Successful Treatment of Atopic Hand and Foot Eczema With Oral Janus Kinase 1 Inhibition

Sitaru, Sebastian; Preis, Sarah; Eberlein, Bernadette

doi:10.1089/derm.2022.0030

Cited by 3 publications

(4 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date, only 1 case report has been published on the effectiveness of abrocitinib on HE, demonstrating positive results in atopic HE ( 13 ). The current study showed that abrocitinib improved HE in patients with AD.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Real-world Experience of Abrocitinib Treatment in Patients with Atopic Dermatitis and Hand Eczema: Up to 28-week Results from the BioDay Registry

Kamphuis,

Boesjes,

Loman

et al. 2024

Acta Derm Venereol

View full text Add to dashboard Cite

Limited daily practice data on the effect of abrocitinib in patients with atopic dermatitis are available. The aim of this multicentre prospective study is to evaluate the effectiveness and safety of abrocitinib in patients with atopic dermatitis treated in daily practice. In a subgroup, the effectiveness of abrocitinib on hand eczema was evaluated. A total of 103 patients from the BioDay registry were included in the study: week 4 (n = 95), week 16 (n = 61) and week 28 (n = 39). At week 28, the Eczema Area and Severity Index (EASI)-50/75/90 was achieved by 81.8%, 57.6%, and 18.2%, respectively, and the weekly average pruritus numerical rating scale ≤ 4 by 62.9%. The effectiveness of abrocitinib was not significantly different between dupilumab non-responders and dupilumab-naïve patients/responders, and between upadacitinib non-responders and upadacitinib-naïve patients/responders. Mean ± standard deviation Hand Eczema Severity Index decreased from 27.4 ± 27.7 at baseline to 7.7 ± 12.1 at week 28 (n = 31). Thirty-two patients (31.1%) discontinued treatment due to ineffectiveness (n = 17), adverse events (n = 9) or both (n = 3). The most frequently reported adverse event was nausea (n = 28). In conclusion, abrocitinib is an effective treatment for atopic dermatitis and can be effective for patients with previous inadequate response to dupilumab or upadacitinib. Furthermore, hand eczema can improve in patients treated with abrocitinib for atopic dermatitis.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Currently, only 2 small single-centre studies are available regarding the effect of abrocitinib on AD in daily practice ( 11 , 12 ). In addition, 1 case report on the effectiveness of abrocitinib on HE has been published ( 13 ).…”

mentioning

confidence: 99%

Real-world Experience of Abrocitinib Treatment in Patients with Atopic Dermatitis and Hand Eczema: Up to 28-week Results from the BioDay Registry

Kamphuis,

Boesjes,

Loman

et al. 2024

Acta Derm Venereol

View full text Add to dashboard Cite

show abstract

“…The study of abrocitinib on HE was limited. Sitaru et al ( 10 ) reported a case of refractory hand and foot eczema was successfully treated with abrocitinib. Kamphuis et al ( 11 ) demonstrated that abrocitinib improved HE in patients with AD in which 13/17 of the patients achieved clear or almost clear and 60% of the patients achieved HECSI 90 at week 16.…”

Section: Discussionmentioning

confidence: 99%

“…It blocks IL-4, IL-13, IL-31, and IFN-γ pathways, which are involved in the pathogenesis of HE ( 9 ). However, the efficacy of abrocitinib on difficult-to-treat HE in real-world is limited ( 10 , 11 ). Here, we reported the effectiveness and safety of abrocitinib on difficult-to-treat HE patients in daily practice.…”

mentioning

confidence: 99%

Real-world Experience of Abrocitinib on Difficult-to-treat Hand Eczema in Chinese Patients

Li,

Tan,

Nie

et al. 2024

Acta Derm Venereol

View full text Add to dashboard Cite

show abstract

Treatment of Refractory Hand and Foot Eczema with Nail Involvement Using Upadacitinib: A Case Report

Yu,

Zhao,

Lin

et al. 2024

Dermatitis®

View full text Add to dashboard Cite

Successful Treatment of Atopic Hand and Foot Eczema With Oral Janus Kinase 1 Inhibition

Cited by 3 publications

References 4 publications

Real-world Experience of Abrocitinib Treatment in Patients with Atopic Dermatitis and Hand Eczema: Up to 28-week Results from the BioDay Registry

Real-world Experience of Abrocitinib Treatment in Patients with Atopic Dermatitis and Hand Eczema: Up to 28-week Results from the BioDay Registry

Real-world Experience of Abrocitinib on Difficult-to-treat Hand Eczema in Chinese Patients

Treatment of Refractory Hand and Foot Eczema with Nail Involvement Using Upadacitinib: A Case Report

Contact Info

Product

Resources

About